alanine and Headache
alanine has been researched along with Headache in 3 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"To characterize clinical features of a very large pedigree with early-onset Alzheimer disease (AD) in which all affected individuals carry the identical glutamic acid-to-alanine mutation at codon 280 in the presenilin-1 gene." | 3.69 | Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. ( Arango-Lasprilla, JC; Arango-Viana, JC; Arcos-Burgos, M; Ardilla, A; Behrens, IM; Goate, AM; Hincapíe, L; Kosik, KS; Lemere, CA; Lendon, C; Lopera, F; Madrigal, L; Martínez, A; Norton, J; Ossa, JE; Rosselli, M; Ruiz-Linares, A, 1997) |
Research
Studies (3)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Sax, PE | 1 |
Wohl, D | 1 |
Yin, MT | 1 |
Post, F | 1 |
DeJesus, E | 1 |
Saag, M | 1 |
Pozniak, A | 1 |
Thompson, M | 1 |
Podzamczer, D | 1 |
Molina, JM | 1 |
Oka, S | 1 |
Koenig, E | 1 |
Trottier, B | 1 |
Andrade-Villanueva, J | 1 |
Crofoot, G | 1 |
Custodio, JM | 1 |
Plummer, A | 1 |
Zhong, L | 1 |
Cao, H | 1 |
Martin, H | 1 |
Callebaut, C | 1 |
Cheng, AK | 1 |
Fordyce, MW | 1 |
McCallister, S | 1 |
Lopera, F | 1 |
Ardilla, A | 1 |
Martínez, A | 1 |
Madrigal, L | 1 |
Arango-Viana, JC | 1 |
Lemere, CA | 1 |
Arango-Lasprilla, JC | 1 |
Hincapíe, L | 1 |
Arcos-Burgos, M | 1 |
Ossa, JE | 1 |
Behrens, IM | 1 |
Norton, J | 1 |
Lendon, C | 1 |
Goate, AM | 1 |
Ruiz-Linares, A | 1 |
Rosselli, M | 1 |
Kosik, KS | 1 |
Stanley, RJ | 1 |
Melson, GL | 1 |
Cubillo, E | 1 |
Hesker, AE | 1 |
Clinical Trials (4)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Trea[NCT01780506] | Phase 3 | 872 participants (Actual) | Interventional | 2012-12-26 | Completed | ||
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treat[NCT01797445] | Phase 3 | 872 participants (Actual) | Interventional | 2013-03-12 | Completed | ||
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994] | 275 participants (Actual) | Observational [Patient Registry] | 2018-02-06 | Active, not recruiting | |||
Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) - A Phase II Exploratory Study[NCT04004702] | Phase 2 | 65 participants (Anticipated) | Interventional | 2020-01-31 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline in CD4+ Cell Count at Week 144
(NCT01780506)
Timeframe: Baseline; Week 144
Intervention | cells/µL (Mean) |
---|---|
E/C/F/TAF | 323 |
E/C/F/TDF | 310 |
Change From Baseline in CD4+ Cell Count at Week 48
(NCT01780506)
Timeframe: Baseline; Week 48
Intervention | cells/µL (Mean) |
---|---|
E/C/F/TAF | 235 |
E/C/F/TDF | 221 |
Change From Baseline in CD4+ Cell Count at Week 96
(NCT01780506)
Timeframe: Baseline; Week 96
Intervention | cells/µL (Mean) |
---|---|
E/C/F/TAF | 285 |
E/C/F/TDF | 271 |
Change From Baseline in Serum Creatinine at Week 144
(NCT01780506)
Timeframe: Baseline; Week 144
Intervention | mg/dL (Mean) |
---|---|
E/C/F/TAF | 0.04 |
E/C/F/TDF | 0.08 |
Change From Baseline in Serum Creatinine at Week 48
(NCT01780506)
Timeframe: Baseline; Week 48
Intervention | mg/dL (Mean) |
---|---|
E/C/F/TAF | 0.08 |
E/C/F/TDF | 0.11 |
Change From Baseline in Serum Creatinine at Week 96
(NCT01780506)
Timeframe: Baseline; Week 96
Intervention | mg/dL (Mean) |
---|---|
E/C/F/TAF | 0.05 |
E/C/F/TDF | 0.07 |
Percent Change From Baseline in Hip BMD at Week 144
Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.826 |
E/C/F/TDF | -3.475 |
Percent Change From Baseline in Hip BMD at Week 96
Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.951 |
E/C/F/TDF | -3.515 |
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01780506)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.865 |
E/C/F/TDF | -3.200 |
Percent Change From Baseline in Spine BMD at Week 144
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.809 |
E/C/F/TDF | -3.023 |
Percent Change From Baseline in Spine BMD at Week 48
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -1.337 |
E/C/F/TDF | -2.956 |
Percent Change From Baseline in Spine BMD at Week 96
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.907 |
E/C/F/TDF | -3.053 |
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | -24.6 |
E/C/F/TDF | 60.4 |
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | -32.8 |
E/C/F/TDF | 18.0 |
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | -33.5 |
E/C/F/TDF | 32.5 |
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 144
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | 37.4 |
E/C/F/TDF | 106.9 |
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | 11.3 |
E/C/F/TDF | 75.0 |
Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | 6.9 |
E/C/F/TDF | 51.2 |
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF | 93.1 |
E/C/F/TDF | 92.8 |
Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 144
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 144 weeks
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | |
E/C/F/TAF | 31.3 | 6.0 | 0.2 |
E/C/F/TDF | 37.1 | 7.0 | 0.2 |
Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 48 weeks
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | |
E/C/F/TAF | 25.8 | 4.6 | 0 |
E/C/F/TDF | 32.3 | 4.9 | 0.2 |
Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 96 weeks
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | |
E/C/F/TAF | 28.8 | 5.1 | 0.2 |
E/C/F/TDF | 33.9 | 5.8 | 0.2 |
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48, 96, and 144
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 48, 96. and 144
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Week 48 | Week 96 | Week 144 | |
E/C/F/TAF | 86.4 | 84.4 | 84.6 |
E/C/F/TDF | 87.3 | 83.6 | 80.1 |
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 and 144
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 96 and 144
Intervention | percentage of participants (Number) | |
---|---|---|
Week 96 | Week 144 | |
E/C/F/TAF | 89.2 | 86.9 |
E/C/F/TDF | 88.2 | 83.1 |
Change From Baseline in CD4+ Cell Count at Week 48
(NCT01797445)
Timeframe: Baseline; Week 48
Intervention | cells/µL (Mean) |
---|---|
E/C/F/TAF | 225 |
E/C/F/TDF | 200 |
Change From Baseline in CD4+ Cell Count at Week 96
(NCT01797445)
Timeframe: Baseline; Week 96
Intervention | cells/µL (Mean) |
---|---|
E/C/F/TAF | 274 |
E/C/F/TDF | 260 |
Change From Baseline in Serum Creatinine at Week 48
(NCT01797445)
Timeframe: Baseline; Week 48
Intervention | mg/dL (Mean) |
---|---|
E/C/F/TAF | 0.08 |
E/C/F/TDF | 0.12 |
Change From Baseline in Serum Creatinine at Week 96
(NCT01797445)
Timeframe: Baseline; Week 96
Intervention | mg/dL (Mean) |
---|---|
E/C/F/TAF | 0.04 |
E/C/F/TDF | 0.07 |
Percent Change From Baseline in Hip BMD at Week 96
Hip BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.364 |
E/C/F/TDF | -3.023 |
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01797445)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.420 |
E/C/F/TDF | -2.603 |
Percent Change From Baseline in Spine BMD at Week 48
Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -1.278 |
E/C/F/TDF | -2.759 |
Percent Change From Baseline in Spine BMD at Week 96
Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -1.017 |
E/C/F/TDF | -2.516 |
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | -29.3 |
E/C/F/TDF | 32.3 |
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | -31.0 |
E/C/F/TDF | 35.2 |
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | 16.9 |
E/C/F/TDF | 73.7 |
Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | 13.3 |
E/C/F/TDF | 51.7 |
Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF | 91.6 |
E/C/F/TDF | 88.5 |
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF | 84.0 |
E/C/F/TDF | 82.3 |
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48 and 96
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Weeks 48 and 96
Intervention | percentage of participants (Number) | |
---|---|---|
Week 48 | Week 96 | |
E/C/F/TAF | 82.4 | 78.7 |
E/C/F/TDF | 80.7 | 76.8 |
Percentage of Participants With Treatment-emergent Proteinuria Through Week 48
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 48
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | |
E/C/F/TAF | 27.3 | 4.7 | 0 |
E/C/F/TDF | 31.6 | 4.6 | 0 |
Percentage of Participants With Treatment-emergent Proteinuria Through Week 96
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 96
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | |
E/C/F/TAF | 31.8 | 5.4 | 0 |
E/C/F/TDF | 36.9 | 5.1 | 0 |
Trials
2 trials available for alanine and Headache
Other Studies
1 other study available for alanine and Headache
Article | Year |
---|---|
Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation.
Topics: Adult; Age of Onset; Alanine; Alzheimer Disease; Autopsy; Brain; Codon; Female; Glutamic Acid; Heada | 1997 |